• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA issues complete response to Protalix

FDA issues complete response to Protalix

March 1, 2011
CenterWatch Staff

The FDA has issued a complete response letter for Protalix's Gaucher's disease drug taliglucerase alfa. Protalix won't be required to conduct any additional clinical studies, but that didn't stop its stock from plunging on the news, FierceBiotech reported.

The FDA's main concerns were with clinical and chemistry, manufacturing and controls. The agency wants additional data from Protalix's switchover trial and long-term extension trial. At the time the NDA was submitted, full information from these trials was not available, the company noted in a release. The FDA wants information on testing specifications and assay validation.

"While we are disappointed by the receipt of the Complete Response Letter, we appreciate the FDA's efforts to complete the review of our NDA,” said Protalix CEO David Aviezer. “We noted that the FDA did not request additional clinical studies. Moreover, the FDA inspected our manufacturing facilities, finding them acceptable. FDA also did not identify any issues in its audit of our clinical sites." The company said it will meet with the FDA to determine its next steps.

Gaucher's is a rare genetic disease in which lipids accumulate in the organs, resulting in organ enlargement and bone pain. Pfizer has partnered with Protalix since 2009 on the drug, an oral recombinant protein therapeutic. If approved, taliglucerase alfa could erode market share of Genzyme's Cerezyme, which has faced shortages due to manufacturing problems.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing